The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: Results from an exploratory study

Archives of Dermatology

Volumn 146, Issue 1, 2010, Pages 57-62

  Yan, Albert C ^a   Honig, Paul J ^a   Ming, Michael E ^b   Weber, Janice ^a   Shah, Kara N ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ELECTROLYTE; GLUCOSE; NITROGEN; PIMECROLIMUS; UREA;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; CASE REPORT; CHILD; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CREAM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ERYTHRODERMA; EXPLORATORY RESEARCH; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; ICHTHYOSIS; ICHTHYOSIS LINEARIS CIRCUMFLEXA; LIVER FUNCTION TEST; NETHERTON DISEASE; OPEN STUDY; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL;

ADMINISTRATION, TOPICAL; CALCINEURIN; CHILD; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ECZEMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; NETHERTON SYNDROME; OINTMENTS; QUALITY OF LIFE; SKIN; SKIN ABSORPTION; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 74549128649     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.326     Document Type: Article

References (20)

1. Netherton syndrome. Online Mendelian Inheritance in Man Web site. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=256500. Accessed September 27, 2008.
2. Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. 2000;25(2):141-142.
3. Safety study of Elidel (pimecrolimus) 1% cream to treat Netherton syndrome. http://www.clinicaltrials.gov/ct2/show/NCT00208026?term= Albert+Yan&rank=1. Accessed October 19, 2008.
4. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949.
5. Holme SA, Man I, Sharpe SL, Dykes PS, Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index: validation of the cartoon version. Br J Dermatol. 2003;148(2):285-290.
6. Halverstam CP, Vachharajani A, Mallory SB. Cushing syndrome from percutaneous absorption of 1% hydrocortisone ointment in Netherton syndrome. Pediatr Dermatol. 2007;24(1):42-45.
7. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol. 2001;137(6):747-750.
8. Shah KN, Yan AC. Low but detectable serum levels of tacrolimus seen with the use of very dilute, extemporaneously compounded formulations of tacrolimus ointment in the treatment of patients with Netherton syndrome. Arch Dermatol. 2006;142(10):1362-1363.
9. Saif GB, Al-Khenaizan S. Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings. Int J Dermatol. 2007;46(3):290-294.
10. Henno A, Choffray A, De La Brassinne M. Improvement of Netherton syndrome associated erythroderma in two adult sisters through use of topical tacrolimus [in French]. Ann Dermatol Venereol. 2006;133(1):71-72.
11. Oji V, Beljan G, Beier K, Traupe H, Luger TA. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br J Dermatol. 2005;153(5):1067-1068.
12. Meingassner JG, Aschauer H, Stuetz A, Billich A. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp Dermatol. 2005;14(10):752-757.
13. Billich A, Aschauer H, Aszodi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004;269(1):29-35.
14. Gottlieb AB, Griffiths CE, Ho VC, et al; Multi-Centre Investigator Group. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol. 2005; 152(6):1219-1227.
15. Wolff K, Fleming C, Hanifin J, et al; Multicentre Investigator Group. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. Br J Dermatol. 2005;152(6):1296-1303.
16. US Food and Drug Administration Web site. http://www.fda.gov/Drugs/ DrugSafety/PublicHealthAdvisories/ucm051760.htm. Accessed October 22, 2009.
17. Pimecrolimus (marketed as Elidel cream). US Food and Drug Administration Web site. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm153524.htm. Accessed October 22, 2009.
18. US Food and Drug Administration Web site. http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107845.htm. Accessed October 22, 2009.
19. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology. 2007;214(4):289-295.
20. Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127(4):808-816.